INCY - Aclaris draws second downgrade despite Phase 2 win for eczema therapy
2024-01-11 07:53:52 ET
More on Aclaris Therapeutics
- Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report
- Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy
- Aclaris posts topline data from mid-stage trial for eczema therapy
- Seeking Alpha’s Quant Rating on Aclaris Therapeutics
- Historical earnings data for Aclaris Therapeutics
For further details see:
Aclaris draws second downgrade despite Phase 2 win for eczema therapy